Ziprasidone: all 97 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I DisorderTerminatedNCT03768726Phase 3Results posted
- Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I DisorderTerminatedNCT02075047Phase 3Results posted
- 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight GainTerminatedNCT01844700Phase 4Results posted
- Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder (Zip Ad)CompletedNCT01293825Phase 4Results posted
- The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) StudyCompletedNCT01211522Phase 3Results posted
- Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)CompletedNCT01172652Phase 4Results posted
- Predictors of Response to Augmentation With Ziprasidone (Geodon®) in Major Depressive DisorderCompletedNCT01168674Phase 4Results posted
- One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic SyndromeTerminatedNCT01113541Phase 3Results posted
- One-Year Trial Of Oral Ziprasidone In Patients With Metabolic SyndromeTerminatedNCT00748566Phase 4Results posted
- A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With AgitationCompletedNCT00723606Phase 3Results posted
- Ziprasidone in the Psychosis ProdromeCompletedNCT00635700Phase 2Results posted
- Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIsCompletedNCT00633399Phase 2Results posted
- Ziprasidone in Pediatric Bipolar DisorderCompletedNCT00622739Phase 4Results posted
- A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive DisorderCompletedNCT00555997Phase 2Results posted
- Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to ZiprasidoneCompletedNCT00538642Not applicableResults posted
- Glucose and Lipid Metabolism on Antipsychotic MedicationCompletedNCT00515723Not applicableResults posted
- Safety Study of Ziprasidone (Geodon) for the Depressive Mixed StateCompletedNCT00490542Phase 2Results posted
- Adjunctive Ziprasidone in the Treatment of Bipolar I DepressionCompletedNCT00483548Phase 3Results posted
- Geodon in Weight Loss Study for Bipolar DisordersCompletedNCT00472641Phase 4Results posted
- Efficacy and Tolerability of Switching to Ziprasidone From Other AntipsychoticsCompletedNCT00458211Phase 4Results posted
- Open-label Ziprasidone Study for Psychosis Treatment in AdolescentsCompletedNCT00421954Phase 3Results posted
- Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To ZiprasidoneCompletedNCT00406315Phase 4Results posted
- Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar DisorderTerminatedNCT00374543Phase 4Results posted
- Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes MellitusCompletedNCT00351000Phase 4Results posted
- Ziprasidone vs. Sertraline/Haloperidol in Psychotic DepressionCompletedNCT00340379Phase 2/3Results posted
- Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for DiabetesCompletedNCT00338949Phase 4Results posted
- Ziprasidone And Olanzapine's Outcomes In ManiaTerminatedNCT00329108Phase 4Results posted
- 3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic SubjectsCompletedNCT00312494Phase 3Results posted
- Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic ChangesTerminatedNCT00288353Phase 3Results posted
- A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.CompletedNCT00282464Phase 3Results posted
- Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)CompletedNCT00280566Phase 3Results posted
- Safety And Tolerability Of Ziprasidone In Adolescents With SchizophreniaTerminatedNCT00265382Phase 3Results posted
- Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)CompletedNCT00265330Phase 3Results posted
- Safety And Efficacy Of Ziprasidone In Adolescents With SchizophreniaTerminatedNCT00257192Phase 3Results posted
- Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)CompletedNCT00257166Phase 3Results posted
- Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major DepressionCompletedNCT00237666Phase 4Results posted
- Geodon for the Treatment of Refractory Social Anxiety DisorderCompletedNCT00215150Phase 2Results posted
- Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031CompletedNCT00174447Phase 3Results posted
- A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I DepressionCompletedNCT00141271Phase 3Results posted
- Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With SchizophreniaCompletedNCT00139737Phase 3Results posted
- Switching Medication to Treat SchizophreniaCompletedNCT00044655Phase 4Results posted
- Reducing the Abuse Liability of Prescription OpioidsCompletedNCT04587115Early Phase 1
- Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model BuildingStatus unknownNCT04446234Phase 4
- Reducing the Abuse of Opioids in Drug UsersTerminatedNCT03837860Early Phase 1
- Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For SchizophreniaActive, not recruitingNCT03781115Phase 1
- Gene-by-Stress Interactions in Intervention Studies SignificanceTerminatedNCT03011645Phase 1
- The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic AgitationStatus unknownNCT02935998Phase 4
- The Role of miR-30 Family Dysregulation in Response to Antipsychotic TreatmentStatus unknownNCT02650102Phase 1/2
- Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-upCompletedNCT02534363Phase 4
- Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-upCompletedNCT02526030Phase 4
- Pharmacovigilance in Gerontopsychiatric PatientsTerminatedNCT02374567Phase 3
- Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic PatientsCompletedNCT02307396Phase 4
- Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective PsychosisCompletedNCT02305823Phase 4
- Comparative Efficacy and Acceptability of Antimanic Drugs in Acute ManiaStatus unknownNCT01893229Phase 4
- Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic SyndromeCompletedNCT01714011Phase 4
- Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed ConditionsCompletedNCT01581879Phase 1
- Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting ConditionsCompletedNCT01581866Phase 1
- Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy EvaluationCompletedNCT01485692Not applicable
- Effectiveness of Ziprasidone for Patients With SchizophreniaCompletedNCT01198353Phase 4
- Antipsychotics and Gene Expression in Soft TissuesCompletedNCT01185743Phase 4
- Efficacy and Safety With Ziprasidone in First-episode PsychosisCompletedNCT01157559Phase 4
- Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)WithdrawnNCT01124877Phase 3
- Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196)WithdrawnNCT01117220Phase 3
- Ziprasidone in Early Onset Schizophrenia Spectrum DisordersCompletedNCT01006551Phase 2
- An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar DepressionCompletedNCT00835107Phase 4
- 24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET StudyCompletedNCT00818298Not applicable
- Ziprasidone vs Standard Therapy for Agitated Patients in the EDWithdrawnNCT00786318Phase 4
- Ziprasidone for Severe Conduct and Other Disruptive Behavior DisordersCompletedNCT00676429Phase 2
- A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic DisordersCompletedNCT00650611Phase 2
- A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective DisorderCompletedNCT00650429Phase 4
- A Study Comparing the Efficacy and Tolerability of Ziprasidone vs. Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic DrugsCompletedNCT00649844Phase 3
- A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic DrugsCompletedNCT00649064Phase 4
- A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic SchizophreniaTerminatedNCT00645515Phase 3
- A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese PatientsCompletedNCT00645372Phase 3
- A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous StudyCompletedNCT00645320Phase 4
- A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective DisorderTerminatedNCT00645229Phase 3
- A Study of the Efficacy and Safety of Intramuscular Ziprasidone Followed by Oral Ziprasidone for the Treatment of PsychosisCompletedNCT00644800Phase 4
- Ziprasidone in the Treatment of Borderline Personality DisorderCompletedNCT00635921Phase 2
- A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized PatientsCompletedNCT00634348Phase 4
- Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)CompletedNCT00418171Phase 4
- Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective DisorderCompletedNCT00395031Phase 2/3
- Switch Study of Existing Atypical Antipsychotics to BifeprunoxCompletedNCT00347425Phase 3
- Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia.CompletedNCT00239109Phase 4
- Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)CompletedNCT00229385Not applicable
- Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective TrialCompletedNCT00224315Phase 4
- Ziprasidone in Children With Autism: A Pilot StudyCompletedNCT00208559Phase 2
- Geodon (Ziprasidone) for Posttraumatic Stress DisorderCompletedNCT00208208Phase 4
- Pfizer/IVGTT/Ziprasidone/OlanzapineCompletedNCT00205725Not applicable
- Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic IllnessCompletedNCT00199940Phase 4
- Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar DisorderCompletedNCT00181922Phase 4
- 12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic PatientsTerminatedNCT00159757Phase 4
- Energy Homeostasis Under Treatment With Atypical AntipsychoticsCompletedNCT00148564Phase 4
- Kahn Study; Investigation Of The Efficacy Of Ziprasidone Versus Olanzapine In The Management Of Recent-Onset Psychosis; A Flexible-Dose, Parallel Group, Double-Blind StudyCompletedNCT00145444Phase 3
- Mozart Relapse StudyCompletedNCT00143351Phase 3
- Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective DisorderCompletedNCT00137020Phase 4
- IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)CompletedNCT00136994Phase 3
- The MIND Study: Modifying the INcidence of DeliriumCompletedNCT00096863Phase 2